US ▾
ZEPP
Earnings call · Jun 2026 (Q2 FY26)

Zepp Health Q2 FY26 earnings call ZEPP

Sep 2, 2026 Source

Executive summary

Zepp Health Q2 FY26 — Revenue Growth Returns with Improved Product Mix and Gross Margin

Zepp Health returned to year-over-year revenue growth in Q2 FY26, driven by new product launches and a strategic shift towards higher-value offerings, which also bolstered gross margins despite cost headwinds. The company is navigating supply constraints and macroeconomic pressures, leading to a projected Q3 revenue decline, but remains focused on product innovation, brand building, and disciplined cost management to achieve sustainable, high-quality growth. Management highlighted the increasing importance of product design and engineering capabilities in differentiating its portfolio.

Highlights

5
  • Revenue grew 6.9% year-over-year to $63.5 million, marking a return to growth.

  • Gross margin improved by 120 basis points year-over-year to 37.4%, despite higher memory and component costs.

  • Product mix shifted towards higher-value products, with T-Rex high-end models accounting for ~50% of activations and Active family establishing a new $169 price tier.

  • Cash and cash equivalents increased by $11 million year-over-year and $3 million sequentially to $106.3 million, driven by enhanced working capital efficiency.

  • Successfully converted $13.3 million of short-term debt into long-term obligations, extending maturity profile.

Concerns

4
  • Q3 FY26 revenue guidance of $68 million to $73 million represents a year-over-year decline of 4% to 10%, attributed to macroeconomic conditions and supply constraints.

  • Adjusted operating loss widened to $11.1 million in Q2 FY26 from $4.9 million in Q2 FY25, primarily due to higher selling and marketing investments and foreign currency impacts.

  • Higher memory and component costs created pressure on profitability, particularly for entry-level products, partially offsetting product mix benefits.

  • Supply bottlenecks affected Bip and Helio Strap products, with Helio Strap not expected to be fully restored until Q4 FY26.

Guidance & targets

CategoryTargetConfidence
Revenue
$68 million to $73 million
high materiality
High
Bip family pricing
increase prices
medium materiality
High

Product announcements

ProductTypeDetails
T-Rex 3 Pro and T-Rex Ultra 2launch
Active 3 Premium and Active Maxlaunch
Balance 3 and Balance Ultralaunch
Helio Strap Prolaunch

Deals & partnerships

HYROX sustained engagement with the HYROX and Hybrid Training communities

This partnership is part of strategic brand-building initiatives and supports the Hybrid Training strategy.

Risks & headwinds

Higher memory and component costs Q2 FY26 and looking to the second half

affected profitability across multiple product families with a greater relative impact on entry-level products

Mitigation:securing sufficient supply through multiple channels, optimizing memory requirements across designs, leveraging engineering expertise, potential benefit from resolution of prior duties paid

Foreign exchange fluctuations Q2 FY26 and H1 FY26

appreciation of RMB partially offset benefits from improved product mix and margin expansion; approximately $2.7 million impact on adjusted operating expenses; approximately $4.5 million impact on H1 FY26 net loss

Mitigation:managing the headwind safely without losing sight of large opportunities

Supply bottlenecks for Bip and Helio Strap Q2 FY26, Q3 FY26, Q4 FY26

constrained Bip and Helio Strap during Q2 FY26; Helio Strap supply expected to recover partially in Q3 and fully restored in Q4

Mitigation:working towards resolving them; Q3 guidance incorporates impact; expecting full supply in Q4

Macroeconomic conditions / inflation Q3 FY26

consumers are pressed on discretionary income and squeezed; contributes to expected Q3 FY26 revenue decline of 4% to 10%

Mitigation:managing pricing, product positioning, and growth quality; expanding contribution of higher-value products; improving unit economics of entry-level portfolio

Manufacturing difficulties for Balance 3 Q2 FY26, Q3 FY26

couldn't manufacture them good enough; lot of difficulties in building them

Mitigation:resolving them as we speak; contributes to Q3 guidance

What to watch in Q3 FY26

Helio Strap supply restoration

Q4 FY26
Current recovering partially in Q3
Target fully restored

Why it matters

Full supply restoration is crucial for Helio Strap to make a more meaningful contribution and strengthen the broader training and recovery ecosystem, impacting revenue potential.

But on Helio Strap, we are gradually working on fully restore the supply bottleneck. So in Q3, you will still see the impact of the supply constraint a little bit, but that has already been reflected in the guidance, which we have provided and in Q4, we're expecting the Helio Strap to be in full supply.

Q&A highlights

When will supply issues for Bip and Helio Strap be fully resolved, and is supply sufficient for Q4 demand?

Bip supply bottlenecks are almost resolved. Helio Strap supply will gradually recover in Q3, with full restoration expected in Q4. Q3 guidance already reflects the impact of these constraints.

“But on Helio Strap, we are gradually working on fully restore the supply bottleneck. So in Q3, you will still see the impact of the supply constraint a little bit, but that has already been reflected in the guidance, which we have provided and in Q4, we're expecting the Helio Strap to be in full supply.”

asked by Siddharth Rajeev · answered by Leon Cheng Deng

2 min read 7 chapters

Detailed narrative

Product Mix Premiumization

Zepp Health is strategically shifting its product portfolio towards higher-value offerings. The T-Rex family has established a mature high-end structure, with T-Rex 3 Pro and T-Rex Ultra 2 (priced at $399 and $549 respectively) consistently accounting for approximately 50% of recent global T-Rex activations. The Active family successfully expanded into a new $169 price tier, increasing its share of global Active family acquisitions from 22% in Q1 to 40% in Q2, reaching 57% by August.

Hybrid Training Strategy

The Balance family exemplifies the company's focus on Hybrid Training, with Balance 3 and Balance Ultra (starting at $369.99 and $599.99 respectively) quickly gaining adoption. These new generation products increased from 3% of global Balance family activations in Q2 to 30% by August, driving a one-third increase in total Balance family activations in July compared to the Q2 monthly average. This strategy leverages deep engagement with the HYROX and Hybrid Training communities.

Design and Engineering as a Differentiator

The company emphasizes its investment in product design language, craftsmanship, and sophisticated industrial design, particularly visible in the new Balance generation. This capability allows for the use of more refined materials while maintaining high levels of GPS connectivity, sensor, and export performance, positioning it as a key technological differentiator in the market.

Entry-Level Portfolio and Pricing Discipline

The entry-level Zepp family, anchored by Bip 6 (priced at $79.99), continues to demonstrate strong consumer demand and product competitiveness, supported by a vertically integrated technology stack allowing for software-driven improvements. To address higher memory and component costs and ensure sustainable unit economics, Zepp Health announced a price increase across the entire Bip family starting January 2027.

Screen-Free Wearables and Professional Capabilities

Zepp Health is expanding its screen-free wearable offerings with Helio Strap and Helio Strap Pro, validating the category with Google's Fitbit Air launch. Demand for Helio Strap exceeded supply in Q2, with full supply expected by Q4. The company is also building professional capabilities in running through its Cheetah product line, gaining credibility among elite athletes like Josh Kerr and Yemane Tsegay, whose achievements validate the product's performance.

Cost Headwinds and Mitigation

The company faced cost headwinds from higher memory component prices and RMB appreciation, which partially offset gross margin improvements. Management is actively securing sufficient memory supply through multiple channels and optimizing memory requirements in product designs. They also highlighted potential benefits from the resolution of prior duties paid, which could further mitigate memory costs.

Operating Expense Management

Adjusted operating expenses increased year-over-year due to foreign currency impacts and higher selling and marketing investments, particularly for new product launches. However, R&D expenses were slightly lower year-over-year excluding FX, reflecting selective investment in cutting-edge technologies like AI and disciplined resource allocation. The company expects selling expenses to moderate as the pace of new product launches slows in the second half of the year.

AI-generated summary of the company's earnings call. Not investment advice.